Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.79 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 1/20 | 0.79 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.70 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423782 | 0.86 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL19264910 | 0.86 | SLC12A2 (0.92) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL3079952 | 0.86 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL13297977 | 0.86 | SLC12A2 (0.92) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL4077665 | 0.85 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL14132588 | 0.85 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL10282764 | 0.83 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL28001439 | 0.83 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL14419685 | 0.83 | SLC12A2 (0.66) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 | |
| SCHEMBL12169365 | 0.82 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR2F2RAB9ACXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3696174-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3208272-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1406876-B1 | 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-6969714-B2 | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-6939872-B2 | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1303496-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002004429-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | MKI67, CCNI, CCNT1 | ALDH1A1 1177/4885SMN1; SMN2 2007/4885NR2F2 2878/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | ALDH1A1 2396/4885SMN1; SMN2 2682/4885NR2F2 897/4885 |
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | ALDH1A1 482/4885SMN1; SMN2 2611/4885NR2F2 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.